Article
Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes.
Diabetes - 1 Jul 2018
Rotroff Daniel M, Yee Sook Wah, Zhou Kaixin, Marvel Skylar W, Shah Hetal S, Jack John R, Havener Tammy M, Hedderson Monique M, Kubo Michiaki, Herman Mark A, Gao He, Mychaleckyi Josyf C, McLeod Howard L, Doria Alessandro, Giacomini Kathleen M, Pearson Ewan R, Wagner Michael J, Buse John B, Motsinger-Reif Alison A
Abstract excerpt
Metformin is the first-line treatment for type 2 diabetes (T2D). Although widely prescribed, the glucose-lowering mechanism for metformin is incompletely understood. Here, we used a genome-wide association approach in a diverse group of individuals with T2D from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial to identify common and rare variants associated with HbA1c response to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.